|View printer-friendly version|
“The addition of a license from ERS provides our clients with a robust
CRISPR/Cas9 gene-editing platform,” said Dr.
Charles River biologists employ CRISPR for target screening alone or alongside RNAi screening with the Company’s shRNA library (SilenceSelect®) to create complex, custom knock-in and knockout cell lines with applications throughout the drug discovery continuum. In addition, Charles River has existing partnerships globally for in vivo model creation, including:
a leader in RNA interference technology specializing in the creation
of customized genetically engineered mouse models. (
Animal Resource Center,
University of Tsukuba, one of Japan’s largest production institutes for genetically modified mice. ( Japanonly)
ICS, a leader in mouse and rat creation and phenotyping. (
To learn more about Charles River’s strategic CRISPR/Cas9 initiatives, please visit the Company’s website.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Charles River Laboratories International, Inc.
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations